|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM238043207 |
| 003 |
DE-627 |
| 005 |
20250217002522.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2014 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.3928/23258160-20140430-01
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0793.xml
|
| 035 |
|
|
|a (DE-627)NLM238043207
|
| 035 |
|
|
|a (NLM)24806429
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Eaton, Alexander M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Injection force comparison of the old and new dexamethasone implant insertion needles in porcine eyes and synthetic sclera
|
| 264 |
|
1 |
|c 2014
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.12.2014
|
| 500 |
|
|
|a Date Revised 25.11.2016
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2014, SLACK Incorporated.
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVE: Determine whether the new dexamethasone intravitreal implant (Ozurdex; Allergan, Irvine, CA) injector needle design can reduce the force needed for insertion when compared to the original needle design
|
| 520 |
|
|
|a MATERIALS AND METHODS: In vitro testing assessed the force required for insertion from five new-design and five old-design Ozurdex needles on a synthetic test medium and explanted porcine eyes. Maximum penetration force was measured in grams-force, while the total work of the needle was measured in joules
|
| 520 |
|
|
|a RESULTS: The new design required 29% and 68% less overall work to perform an injection in the synthetic medium (P = .0002) and porcine eyes (P = .009), respectively. The maximum force required to insert the new needle was 25% and 61% that of the old needle in the synthetic medium (P = .001) and porcine eyes (P = .007), respectively
|
| 520 |
|
|
|a CONCLUSION: The new needle design significantly reduces the force and work needed for insertion, which should improve physician control as well as patient safety and comfort
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Drug Implants
|2 NLM
|
| 650 |
|
7 |
|a Glucocorticoids
|2 NLM
|
| 650 |
|
7 |
|a Dexamethasone
|2 NLM
|
| 650 |
|
7 |
|a 7S5I7G3JQL
|2 NLM
|
| 700 |
1 |
|
|a Gordon, Gabriel M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Booth, Dave
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wafapoor, Hussein
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Avery, Robert L
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 45(2014), 3 vom: 24. Mai, Seite 232-8
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnas
|
| 773 |
1 |
8 |
|g volume:45
|g year:2014
|g number:3
|g day:24
|g month:05
|g pages:232-8
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20140430-01
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_63
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_91
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_136
|
| 912 |
|
|
|a GBV_ILN_151
|
| 912 |
|
|
|a GBV_ILN_181
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_217
|
| 912 |
|
|
|a GBV_ILN_235
|
| 912 |
|
|
|a GBV_ILN_289
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_297
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_352
|
| 912 |
|
|
|a GBV_ILN_674
|
| 912 |
|
|
|a GBV_ILN_676
|
| 912 |
|
|
|a GBV_ILN_688
|
| 912 |
|
|
|a GBV_ILN_698
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_737
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_812
|
| 912 |
|
|
|a GBV_ILN_1127
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 45
|j 2014
|e 3
|b 24
|c 05
|h 232-8
|